PRGN-2009

Phase 2Biologic

PRGN-2009 is one of 8 biologic programs targeting Oropharyngeal Squamous Cell Carcinoma (SCC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharyngeal Squamous Cell Carcinoma (SCC)Active, not recruiting

Squamous Cell Carcinoma of the Head and NeckActive, not recruiting

Oropharyngeal Squamous Cell Carcinoma (SCC)Phase 2

Active, not recruiting

Squamous Cell Carcinoma of the Head and NeckPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Squamous Cell Carcinoma of the Head and Neck

#DrugCompanyPhaseTrials

MRG003

SShanghai Miracogen Inc.

Phase 3

1 2

Taxotere

AAvyxa

Phase 2

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 4

Yervoy

Bristol-Myers Squibb

Phase 1

2 5

Opdivo

Bristol-Myers Squibb

Phase 1

1 6

PRGN-2009

NNational Cancer Institute (NCI)

Phase 2

1 7

VX15/2503

VVaccinex Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Squamous Cell Carcinoma of the Head and Neck

NCT06223568

Q3 2030

Phase 2Active, not recruiting

Oropharyngeal Squamous Cell Carcinoma (SCC)

NCT05996523

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma of the Head and Neck1 trial

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06223568·70 enrolled

HPV Positive Cancer1 trial

Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers

Completed·NNational Cancer Institute (NCI)·Preclinical·NCT04432597·39 enrolled

Oropharyngeal Squamous Cell Carcinoma (SCC)1 trial

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05996523·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PRGN-2009. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRGN-2009 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRGN-2009. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

PRGN-2009

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2030

Trials by Indication[1]

Squamous Cell Carcinoma of the Head and Neck1 trial

HPV Positive Cancer1 trial

Oropharyngeal Squamous Cell Carcinoma (SCC)1 trial

References

Drug Info

Quick Facts

Related News